azenosertib
4 abstracts
Abstract
Targeting replication stress in pancreatic cancer: A phase II trial investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic cancer.Org: Dana-Farber Cancer Institute, Boston, MA, Massachusetts General Hospital,
Abstract
Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma.Org: Zentalis Pharmaceuticals,
Abstract
Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC).Org: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Cabrini Research, Malvern, Australia, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina, Linear Cancer Research and University of Western Australia, Nedlands, Western Australia, Australia,
Abstract
A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).Org: Zentalis Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, The James Cancer Hospital and Solove Research Institute, University of Texas M.D. Anderson Cancer Center,